About
Alzheimer’s targeting antibody
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyVirginia, DC, DE & Maryland
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
633
By Phase
PHASE1: 2PHASE2: 1
By Status
COMPLETED: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06511570Lead Sponsor
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
PHASE1Completed
28 participants
Started: Jun 25, 2024 · Completed: Sep 17, 2024
NCT06335173Lead Sponsor
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
PHASE2Active, not recruiting
540 participants
Started: Feb 29, 2024 · Completed: Oct 31, 2026
NCT04931459Lead Sponsor
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
PHASE1Completed
65 participants
Started: Jun 21, 2021 · Completed: Jun 12, 2023
Locations (1)
Headquarters
Charlottesville, VA, United States
Map
Loading map...